A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Cancer

Full Title

A Prospective Clinical Trial to Establish Mesothelin as a Biomarker for the Clinical Management of Barrett’s Esophagus and Esophageal Adenocarcinoma (EAC) Back to top

Purpose

The purpose of this study is to find out whether a protein called mesothelin, which is found in the blood and tissue, can be used as “marker” for esophageal cancer. Investigators are comparing levels of this protein between patients with abnormal esophageal cells or tissue and patients being treated for esophageal cancer. They will see how mesothelin levels correlate with the stage of disease, a patient’s response to treatment, and the risk of recurrence. Doctor hope to identify a marker such as mesothelin that can help guide them in making treatment decisions for their patients.

Back to top

Eligibility

This study includes patients with stage I-III adenocarcinoma of the esophagus who are age 18 or older and are being treated at Memorial Sloan-Kettering Cancer Center.

For more information about this study, please contact Dr. Nabil Rizk or Research Coordinators Alain Vincent or Amanda Ghanie at 212-639-8357.

Back to top

Protocol

11-037

Investigator

Co-Investigators

Locations